Search

everythinglearnresearchcommunity

for

Search:↓

No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.

Ixekizumab has known and some unexpected side effects.

The new drug delivery system effectively targets lung cancer cells.

Expanding CD4+ Tregs can stop hair loss in alopecia areata.

Baricitinib shows promise in treating severe hair loss.

Hit15 shows promise as a COVID-19 treatment by reducing virus infection and inflammation.

Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.

Methotrexate treatment for rheumatoid arthritis has a serious infection rate of about two per 100 patient-years.

Intralesional pentoxifylline effectively and safely treats alopecia areata, improving hair regrowth.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

GT20029 showed some hair growth improvement, but longer studies are needed for better results.

Prostaglandin F2α analogs show promise for treating certain types of hair loss but need more research for other skin conditions.

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.

PPARγ signaling modulation can protect hair follicle stem cells from chemotherapy-induced damage.

Double-spin PRP is more effective for treating male pattern baldness.

The combination therapy effectively treats infertility in PCOS without major side effects.

Letrozole may help prevent seizures by reducing certain hormone levels.

High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.

Treatment improved PCOS symptoms and reduced BMI and certain immune factors.

Both LNG-IUD and systemic progestins are effective for fertility-sparing treatment, but close monitoring is needed due to recurrence risk.

Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.

Baricitinib was effective in treating alopecia areata in two major trials.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.

Intralesional triamcinolone is more effective than topical betamethasone for treating localized alopecia areata.

Higher levels of MIG and IP-10 may help diagnose and monitor Alopecia Areata.

AMP-303 safely increases hair growth in men with hair loss.

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.